Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis

Nenhuma Miniatura disponível
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PHYSICIANS POSTGRADUATE PRESS
Autores
STUCKELMAN, Zachary D.
MULQUEEN, Jilian M.
COHEN, Stephanie C.
COUGHLIN, Catherine G.
LECKMAN, James F.
BLOCH, Michael H.
Citação
JOURNAL OF CLINICAL PSYCHIATRY, v.78, n.6, p.E648-E655, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Irritability is listed as a common side effect of psychostimulant medications. However, psychostimulants have been demonstrated as an effective treatment in reducing irritability and aggression in children with attention-deficit/hyperactivity disorder (ADHD). The goal of this study was to quantify the risk of irritability as a side effect of psychostimulant treatment for ADHD. Data Sources and Study Selection: A PubMed search was conducted on August 18, 2013, to identify all double-blind, randomized, placebo-controlled trials published in English examining the efficacy of psychostimulant medications in the treatment of children with ADHD. Trials were excluded if (1) they required additional psychiatric or medical comorbidity in addition to ADHD, (2) they involved fewer than 20 subjects (parallel group trials), or (3) children received psychostimulant medication for less than 1 week. Data Extraction: A fixed-effects meta-analysis was used to examine the risk ratio of irritability reported as a side effect in children treated with psychostimulants compared to placebo. Stratified subgroup analysis and meta-regression were used to examine the effects of stimulant type, dosage, duration of use, and trial design on the measured risk of irritability. Results: From 92 potentially eligible trials, the meta-analysis identified 32 trials involving 3,664 children with ADHD that reported data on irritability as a side effect. The relative risk of irritability significantly differed between psychostimulant classes (test for subgroup differences.2 1 = 7.6, P =.006). Methylphenidate derivatives were associated with a significantly decreased risk of irritability compared to placebo (risk ratio [RR] = 0.89 [95% CI, 0.82 to 0.96], z = -2.87, P =.004, k = 32, I2 = 50%), whereas amphetamine derivatives were associated with a significantly increased risk of irritability (RR = 2.90 [95% CI, 1.26 to 6.71], z = 2.5, P =.01, k = 5, I2 = 0%). Conclusions: This meta-analysis suggests an increased risk of irritability may be confined to amphetamine-derived psychostimulants. Future meta-analyses examining the effects of amphetamine and methylphenidate derivatives on irritability as a continuous measure, as well as head-to-head trials between methylphenidate and amphetamine derivatives examining effects on irritability, will be important to replicate the findings of this meta-analysis. (C) Copyright 2017 Physicians Postgraduate Press, Inc.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/22093
Referências
  1. AHMANN PA, 1993, PEDIATRICS, V91, P1101
  2. American Psychiatric Association,, 2013, DIAGNOSTIC STAT MANU
  3. Arnold L. E., 2000, J ATTEN DISORD, V3, P200, DOI 10.1177/108705470000300403
  4. BARKLEY RA, 1990, PEDIATRICS, V86, P184
  5. Biederman J, 2007, CLIN THER, V29, P450, DOI 10.1016/j.clinthera.2007.03.006
  6. Brotman MA, 2006, BIOL PSYCHIAT, V60, P991, DOI 10.1016/j.biopsych.2006.08.042
  7. Buitelaar JK, 1996, J CHILD PSYCHOL PSYC, V37, P587, DOI 10.1111/j.1469-7610.1996.tb01445.x
  8. Childress AC, 2009, J CHILD ADOL PSYCHOP, V19, P351, DOI 10.1089/cap.2009.0007
  9. Coccaro EF, 2015, CNS SPECTRUMS, V20, P295, DOI 10.1017/S1092852915000310
  10. CONNERS CK, 1980, ARCH GEN PSYCHIAT, V37, P922
  11. Connor DF, 2002, J AM ACAD CHILD PSY, V41, P253, DOI 10.1097/00004583-200203000-00004
  12. CROWLEY TJ, 1972, PSYCHOPHARMACOLOGIA, V27, P213, DOI 10.1007/BF00422801
  13. de Almeida RMM, 2005, EUR J PHARMACOL, V526, P51, DOI 10.1016/j.ejphar.2005.10.004
  14. de la Cruz L Fernandez, 2015, J AM ACAD CHILD ADOL, V54
  15. Dougherty DD, 2006, DEPRESS ANXIETY, V23, P175, DOI 10.1002/da.20168
  16. DURING MJ, 1992, NEUROSCI LETT, V140, P129, DOI 10.1016/0304-3940(92)90698-7
  17. Efron D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/peds.100.4.662
  18. Ferrari PF, 2003, EUR J NEUROSCI, V17, P371, DOI 10.1046/j.1460-9568.2003.02447.x
  19. Findling RL, 2006, EUR CHILD ADOLES PSY, V15, P450, DOI 10.1007/s00787-006-0565-0
  20. Findling RL, 2011, J AM ACAD CHILD PSY, V50, P395, DOI 10.1016/j.jaac.2011.01.007
  21. Firestone P, 1998, J CHILD ADOL PSYCHOP, V8, P13, DOI 10.1089/cap.1998.8.13
  22. FITZPATRICK PA, 1992, J AM ACAD CHILD PSY, V31, P226, DOI 10.1097/00004583-199203000-00008
  23. Fleckenstein AE, 1999, EUR J PHARMACOL, V382, P45, DOI 10.1016/S0014-2999(99)00588-9
  24. Gadow KD, 2014, J AM ACAD CHILD ADOL, V53
  25. Gadow KD, 2014, J AM ACAD CHILD ADOL, V53, pe1
  26. GITTELMANKLEIN R, 1976, ARCH GEN PSYCHIAT, V33, P1217
  27. Gorman EB, 2006, J AM ACAD CHILD PSY, V45, P808, DOI 10.1097/01.chi.0000214191.57993.dd
  28. GREENBERG LM, 1972, AM J PSYCHIAT, V129, P532
  29. Greenhill LL, 2006, J AM ACAD CHILD PSY, V45, P817, DOI 10.1097/01.chi.0000220847.41027.5d
  30. Greenhill LL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e39
  31. Harpin VA, 2005, ARCH DIS CHILD, V90, pI2, DOI 10.1136/adc.2004.059006
  32. Hess EJ, 1996, J NEUROSCI, V16, P3104
  33. KANTAK KM, 1988, PSYCHOPHARMACOLOGY, V96, P468, DOI 10.1007/BF02180026
  34. KLORMAN R, 1990, J AM ACAD CHILD PSY, V29, P702, DOI 10.1097/00004583-199009000-00005
  35. Kuczenski R, 1997, J NEUROCHEM, V68, P2032
  36. Lee J, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-70
  37. MICZEK KA, 1974, PSYCHOPHARMACOLOGIA, V39, P275, DOI 10.1007/BF00422968
  38. Newcorn JH, 2008, AM J PSYCHIAT, V165, P721, DOI 10.1176/appi.ajp.2007.05091676
  39. Pappadopulos E, 2006, J CAN ACAD CHILD ADO, V15, P27
  40. Pliszka SR, 2000, J AM ACAD CHILD PSY, V39, P619, DOI 10.1097/00004583-200005000-00016
  41. RAPOPORT JL, 1974, ARCH GEN PSYCHIAT, V30, P789
  42. RAPPORT MD, 1985, J ABNORM CHILD PSYCH, V13, P227, DOI 10.1007/BF00910644
  43. Safer Daniel J, 2009, Child Adolesc Psychiatry Ment Health, V3, P35, DOI 10.1186/1753-2000-3-35
  44. Schachar R, 2008, J CHILD ADOL PSYCHOP, V18, P11, DOI 10.1089/cap.2007.0039
  45. Schulz E, 2010, J CHILD ADOL PSYCHOP, V20, P377, DOI 10.1089/cap.2009.0106
  46. Shaw P, 2014, AM J PSYCHIAT, V171, P276, DOI 10.1176/appi.ajp.2013.13070966
  47. Solanto M, 2009, J CHILD ADOL PSYCHOP, V19, P663, DOI 10.1089/cap.2009.0033
  48. Stein MA, 2003, PEDIATRICS, V112, pE404, DOI 10.1542/peds.112.5.e404
  49. Stein MA, 1996, PEDIATRICS, V98, P748
  50. Stringaris A, 2009, J CHILD PSYCHOL PSYC, V50, P216, DOI 10.1111/j.1469-7610.2008.01989.x
  51. Swanson JM, 2004, PEDIATRICS, V113, pE206, DOI 10.1542/peds.113.3.e206
  52. Swenson M, STIMULANT EQUIVALENC
  53. WERRY JS, 1980, J CHILD PSYCHOL PSYC, V21, P27, DOI 10.1111/j.1469-7610.1980.tb00013.x
  54. WERRY JS, 1974, AUST NZ J PSYCHIAT, V8, P9, DOI 10.3109/00048677409159770
  55. Wigal Sharon B, 2009, Child Adolesc Psychiatry Ment Health, V3, P17, DOI 10.1186/1753-2000-3-17
  56. Wigal T, 2006, J AM ACAD CHILD PSY, V45, P1294, DOI 10.1097/01.chi.0000235082.63156.27
  57. Wilens TE, 2010, J CLIN PSYCHIAT, V71, P548, DOI 10.4088/JCP.09m05779pur

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC